Kala Pharmaceuticals (KALA) Tops Q2 EPS by 6c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.38), $0.06 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65